KEYLYNK-012

A study of Pembrolizumab with concurrent chemoradiation therapy followed by Pembrolizumab with or without Olaparib in stage III non-small cell lung cancer (NSCLC)

Study Name:
A study of Pembrolizumab with concurrent chemoradiation therapy followed by Pembrolizumab with or without Olaparib in stage III non-small cell lung cancer (NSCLC).

Targeted Disease(s):
Lung Cancer

Purpose of Study:

This study is looking at how pembrolizumab with chemotherapy and radiation followed by pembrolizumab plus olaparib (or placebo for olaparib) works compared to chemotherapy and radiation followed by durvalumab.

Study Dates:
July 6, 2020 - July 6, 2026

Study Location:
Nationwide

Funding Source:
Merck & Co., Inc.

ClinicalTrails.gov Identifier:
NCT04380636

Register for Trial
Asthma Educator Institute
, | Jul 11, 2022
Community Connections - RSV: The Illness on Every Parent's Radar This Season
, | Feb 08, 2023